论文部分内容阅读
1979年Koprowski等发现糖链抗原CA 19—9,此抗原在胰腺癌等消化系统癌有很高的阳性率,故作为新的肿瘤标记而引人注目。但对CA 19—9在胃及大肠癌的临床研究不多。本文就胃与大肠癌患者测定CA19—9的诊断价值进行研究,并与CEA、IAP、TPA进行比较。 以114例患者进行观察,其中经组织学检查确诊的胃癌68例,大肠癌38例,胃、大肠良性疾病8例。68例胃癌中原发癌59例(Ⅰ期22例、Ⅱ期1例、Ⅲ期14例、Ⅳ期22例),再发癌9例。38例大肠癌中原发癌30例(按Dukes分类,DukesA 4例,Dukes B10例,Dukes C 10例,Dukes D 6例),再发癌8例。对原发
In 1979, Koprowski et al. discovered the carbohydrate antigen CA 19-9, which has a high positive rate in digestive system cancer such as pancreatic cancer and has attracted attention as a new tumor marker. However, there are not many clinical studies on CA 19-9 in gastric and colorectal cancers. In this paper, the diagnostic value of CA19-9 in gastric and colorectal cancer patients was studied and compared with CEA, IAP, and TPA. Observed in 114 patients, of which 68 cases were confirmed by histological examination of gastric cancer, 38 cases of colorectal cancer, 8 cases of benign disease of the stomach and large intestine. There were 59 primary cancers in 68 cases of gastric cancer (22 in stage I, 1 in stage II, 14 in stage III, and 22 in stage IV), and 9 cases recurred. Of the 38 cases of colorectal cancer, 30 were primary (classified by Dukes, Dukes A4, Dukes B10, Dukes C 10, and Dukes D 6), and 8 had recurrent cancer. Primary